Vinorelbine liposomal - Spectrum Pharmaceuticals

Drug Profile

Vinorelbine liposomal - Spectrum Pharmaceuticals

Alternative Names: Alocrest; INX-0125; Liposomal vinorelbine; Sphingosomal vinorelbine; Vinorelbine liposomal; Vinorelbine tartrate injection; Vinorelbine-TCS

Latest Information Update: 17 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Developer Spectrum Pharmaceuticals; Talon Therapeutics
  • Class Antineoplastics; Small molecules; Vinca alkaloids
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Non-Hodgkin's lymphoma; Solid tumours

Highest Development Phases

  • Suspended Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
  • No development reported Breast cancer; Lung cancer

Most Recent Events

  • 17 May 2016 No recent reports on development identified- Phase-I for Breast cancer & Lung cancer in Canada (IV)
  • 30 Sep 2013 Biomarkers information updated
  • 18 Jul 2013 Spectrum Pharmaceuticals acquires Talon Therapeutics' previous rights to liposomal vinorelbine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top